Compare SMFG & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMFG | BSX |
|---|---|---|
| Founded | 2002 | 1979 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.3B | 137.8B |
| IPO Year | 1949 | 1992 |
| Metric | SMFG | BSX |
|---|---|---|
| Price | $21.05 | $93.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $124.44 |
| AVG Volume (30 Days) | 1.8M | ★ 9.9M |
| Earning Date | 01-30-2026 | 02-04-2026 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | N/A | ★ 54.68 |
| EPS | 1.20 | ★ 1.87 |
| Revenue | ★ $23,139,010,382.00 | $19,349,000,000.00 |
| Revenue This Year | $38.96 | $21.05 |
| Revenue Next Year | $4.37 | $11.44 |
| P/E Ratio | ★ $28.17 | $49.47 |
| Revenue Growth | N/A | ★ 21.61 |
| 52 Week Low | $11.83 | $85.98 |
| 52 Week High | $21.54 | $109.50 |
| Indicator | SMFG | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 47.64 |
| Support Level | $20.44 | $90.89 |
| Resistance Level | $21.54 | $93.07 |
| Average True Range (ATR) | 0.23 | 2.34 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 72.89 | 47.04 |
Sumitomo Mitsui Financial Group is roughly tied with Mizuho Financial Group for the status of Japan's second-largest bank after Mitsubishi UFJ Financial Group. As of March 2025, its market share of domestic loans was 7.3%, compared with 8.4% for MUFG. It has a larger consumer finance business than the other two megabanks, owning 100% of the Promise business and SMBC Card. It also controls one of Japan's largest leasing companies and SMBC Aviation Capital, one of the top five aircraft lessors globally. In securities, its SMBC Nikko unit is Japan's third-largest retail broker, although SMFG has lagged somewhat in institutional securities business and asset management.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.